ASCO: Bevacizumab Falls Short Again
(MedPage Today) -- Trial is "technically positive" but won't restore sheen to failed breast cancer drug.
Publication date: Available online 19 June 2019Source: Biosensors and BioelectronicsAuthor(s): Sattar Akbari Nakhjavani, Hadi Afsharan, Balal Khalilzadeh, Mohammad Hossein Ghahremani, Sandro Carrara, Yadollah OmidiAbstractCarcinoembryonic antigen (CEA) is an important oncomarker for the detection of breast cancer. For ultra-sensitive sensing of CEA with great specificity and accuracy, an innovative and reliable electrochemical immunosensor was developed using various nano-hybrids. A glassy carbon electrode (GC) was modified with thiolated graphene oxide (T-GO) to elevate the active surface area of the electrode. The strept...
Publication date: Available online 19 June 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Diana C. Márquez-Garbán, Gang Deng, Begonya Comin-Anduix, Alejandro J. Garcia, Yanpeng Xing, Hsiao-Wang Chen, Gardenia Cheung-Lau, Nalo Hamilton, Michael E. Jung, Richard J. PietrasAbstractBreast cancers (BC) with expression of estrogen receptor-alpha (ERα) occur in more than 70% of newly-diagnosed patients in the U.S. Endocrine therapy with antiestrogens or aromatase inhibitors is an important intervention for BCs that express ERα, and it remains one of the most effective tar...
This study reports characterization of the first breast cancer bone growth model in huNOG mice. BT-474 tumors represent a "cold" tumor with a low number of TILs. This model can be used for evaluating the efficacy of combination treatments of IO therapies with immune-stimulatory compounds or therapeutic approaches on bone metastatic breast cancer. PMID: 31211147 [PubMed - in process]
ConclusionSelect NCCN criteria are associated with higher rates of BRCA mutations. Waiting for genetic testing results to guide surgical management may be warranted in this subset of patients.
ConclusionsIORT is a safe and effective alternative to whole breast radiotherapy, and serves as a suitable alternative to completion mastectomy in locally recurrent breast cancer.Summary for the table of contentsA multidisciplinary breast cancer center experience of intraoperative radiation therapy (IORT) in early stage breast cancer patients. Single high dose IORT was implemented in lieu of prolonged daily whole breast radiation as part of breast conserving therapy. IORT was found to be safe and effective alternative to WBRT in select early stage breast cancer patients.
Condition: Breast Cancer Intervention: Diagnostic Test: SPECT Sponsors: Tomsk National Research Medical Center of the Russian Academy of Sciences; KTH Royal Institute of Technology; Uppsala University Enrolling by invitation
Condition: Breast Cancer Intervention: Drug: Talazoparib Sponsors: Massachusetts General Hospital; Pfizer Not yet recruiting
Conditions: Breast Carcinoma; Mammoplasty Patient Interventions: Procedure: Mammoplasty; Procedure: Vascularized Lymph Node Transfer Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Seno Medical's opto-acoustic technology could reduce false positives and identify cancer sub-types SAN ANTONIO, June 19, 2019 -- (Healthcare Sales &Marketing Network) -- Additional research appearing in the June online issue (open access) of European ... Devices, Radiology Seno Medical, Imagio Breast Imaging, opto-acoustic, imaging
MRI finds breast cancer earlier than digital mammography in women with a family...Read more on AuntMinnie.comRelated Reading: Surveillance breast MRI is double-edged sword ISMRM: Personalized breast cancer screening is at hand ISMRM: Breast MRI confirms lymph node response to therapy SMRT: Abbreviated protocol may address barriers to breast MRI screening ARRS: Is follow-up breast MRI OK for BI-RADS 3 cases?